ReviewUrologie (Heidelberg, Germany)2026
[Reassessing androgen deprivation therapy (ADT) in older men with advanced prostate cancer: when to use, when to discontinue, and role as monotherapy?]
Review in Urologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogen deprivation therapy (ADT) remains the standard of care for the treatment of advanced and metastatic prostate cancer (PC). However, in older patients, the choice of treatment must be made carefully, as they often have comorbidities and are at risk of potential side effects. Newer hormonal therapies (androgen receptor pathway inhibitors, ARPIs) have expanded the treatment spectrum, raising questions about optimal therapy for older patients.
objectiveThis article provides an overview of the evidence-based use of ADT and ARPI in older patients, with a particular focus on relevant guideline recommendations and study results across different stages of prostate cancer. It also describes how individualized treatment decisions can be made in clinical practice. MATERIALS AND
methodsSelective literature review on ADT and ARPI in older patients. Data from relevant clinical trials, current evidence, and recommendations from international and national guidelines (e.g., EAU, S3) are considered.
resultsFor metastatic hormone-sensitive prostate cancer (mHSPC), the combination of ADT and ARPI has proven beneficial, particularly for patients with a life expectancy of more than 1 year and a good performance status. Network meta-analyses show that dual- and triple-agent therapies improve overall survival in older patients, while side effects increase.
conclusionThe use of ADT + ARPI improves survival rates but requires a nuanced assessment of side effects and quality of life, particularly in very old patients. Geriatric assessment helps classify patients into different risk groups and plays a central role in treatment decisions.
Indexed as
Identifiers
42154021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.